scholarly journals Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Claudia Torino ◽  
Patrizia Pizzini ◽  
Sebastiano Cutrupi ◽  
Rocco Tripepi ◽  
Antonio Vilasi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Generalized Linear Model ◽  
Receptor Activation ◽  
Advanced Glycation ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Glycation End Products ◽  
Circulating Levels ◽  
Biomarkers Of Oxidative Stress

Vitamin D receptor (VDR) activation has been reported to increase circulating levels of the advanced glycation end products (AGE) and their decoy receptor (RAGE). However, until now, the effect of VDR activation on AGE and RAGE has not been tested in the setting of a randomized, double-blind clinical trial. We have therefore analyzed the effect of VDR activation by paricalcitol on pentosidine, S100A12/ENRAGE, and RAGE and on established biomarkers of oxidative stress like myeloperoxidase in CKD patients in the PENNY trial. At baseline, human S100A12/ENRAGE, RAGE, and myeloperoxidase, but not pentosidine, were intercorrelated, and the association between S100A12/ENRAGE and myeloperoxidase (r=0.71, P<0.001) was the strongest among these correlations. Paricalcitol failed to modify biomarkers of the AGE/RAGE system and myeloperoxidase in unadjusted and adjusted analyses by the generalized linear model (GLM). No effect modification by other risk factors was registered. Paricalcitol does not modify biomarkers of the AGE/RAGE system and myeloperoxidase in CKD patients. The apparent increase in RAGE levels by VDR activation reported in previous uncontrolled studies is most likely due to confounding factors rather than to VDR activation per se. This trial is registered with NCT01680198.

Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial

2018 ◽  
Vol 34 (5) ◽  
pp. 819-824 ◽  
Author(s):  
Graziella D’arrigo ◽  
Patrizia Pizzini ◽  
Sebastiano Cutrupi ◽  
Rocco Tripepi ◽  
Giovanni Tripepi ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Randomized Trial ◽  
Vitamin D Receptor ◽  
Receptor Activation ◽  
Double Blind ◽  
Soluble Thrombomodulin

scholarly journals Effects of Vitamin D on Endometriosis-Related Pain: A Double-Blind Clinical Trial

2016 ◽  
Vol 22 ◽  
pp. 4960-4966 ◽  
Author(s):  
Fariba Almassinokiani ◽  
Sepideh Khodaverdi ◽  
Masoud Solaymani-dodaran ◽  
Peyman Akbari ◽  
Abdolreza Pazouki
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Double Blind ◽  
Double Blind Clinical Trial

scholarly journals Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes; a randomized double-blind clinical trial

2012 ◽  
Vol 20 (1) ◽  
Author(s):  
Ramin Heshmat ◽  
Ozra Tabatabaei-Malazy ◽  
Shabnam Abbaszadeh-Ahranjani ◽  
Samimeh Shahbazi ◽  
Ghazal Khooshehchin ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Vitamin D ◽  
Anthropometric Parameters ◽  
Double Blind ◽  
Double Blind Clinical Trial

Structural Insights into the Molecular Mechanism of Vitamin D Receptor Activation by Lithocholic Acid Involving a New Mode of Ligand Recognition

2014 ◽  
Vol 57 (11) ◽  
pp. 4710-4719 ◽  
Author(s):  
Anna Y. Belorusova ◽  
Jérôme Eberhardt ◽  
Noëlle Potier ◽  
Roland H. Stote ◽  
Annick Dejaegere ◽  
...  
Keyword(s):  
Vitamin D ◽  
Molecular Mechanism ◽  
Vitamin D Receptor ◽  
Lithocholic Acid ◽  
Receptor Activation ◽  
Ligand Recognition ◽  
Structural Insights

scholarly journals SP322ADIPONECTIN MODIFIES THE FGF23 RESPONSE TO VITAMIN D RECEPTOR ACTIVATION: A RANDOMIZED CLINICAL TRIAL

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i452-i452
Author(s):  
Belinda Spoto ◽  
Patrizia Pizzini ◽  
Giovanni Tripepi ◽  
Francesca Mallamaci ◽  
Carmine Zoccali
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Randomized Clinical Trial ◽  
Vitamin D Receptor ◽  
Receptor Activation

scholarly journals Relationship Between Advanced Glycation End Products and Their Receptor, sRAGE and Cardiovascular Diseases Risk in Adults with T2D and Vitamin D Insufficiency/deficiency (FS12-08-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Justina Owusu ◽  
Fatma Huffman ◽  
Juan Liuzzi ◽  
Tan Li ◽  
Vijaya Narayanan
Keyword(s):  
Blood Pressure ◽  
Vitamin D ◽  
Cardiovascular Diseases ◽  
Advanced Glycation End Products ◽  
Serum Levels ◽  
Vitamin D Insufficiency ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
The Relationship

Abstract Objectives Advanced Glycation End Products, (AGEs) and their soluble receptor (sRAGE) have been implicated in the development of complications and mortality among individuals with type 2 diabetes (T2D). There is limited information on the relationship between AGEs and sRAGE and risk of cardiovascular diseases (CVD) in minority groups, who have a higher burden of T2D. The relationship between AGEs and sRAGE and CVD risks in adults with T2D and vitamin D insufficiency/deficiency was assessed in a minority population. Methods A cross sectional study of Hispanics and African Americans with T2D (n = 64, 41 women and 23 men, mean age = 54 ± 9) recruited from two clinics in Miami Dade. Systolic (SBP) and diastolic blood pressure (DBP), weight and height measurement and serum lipid profile were completed. ELISA kits were used to assess serum levels of AGEs (Biotang Inc/TSZ Elisa, Waltham, MA, USA) and sRAGE (Biotang Inc/TSZ Elisa, Waltham, MA, USA). Multiple linear regression was used to assess association between AGEs, sRAGE and CVD risks. Results A negative and significant association between AGEs and high-density lipoprotein cholesterol (HDL-C)(B = −0.551, P = 0.029) was found. The relationship between AGEs and HDL-C persisted after adjusting for covariates (P < 0.05). sRAGE was significantly associated with SBP (B = 0.015, P = 0.025) and diastolic blood pressure DBP (B = 0.0271, P = 0.037). Results loss significance when association between sRAGE and DBP and SBP were adjusted for covariates such as age, body mass index (BMI), smoking and alcohol intake. Conclusions Our results suggest that AGEs and sRAGE are related to markers of cardiovascular risk such as HDL-C, SBP and DBP in the study population of African Americans and Hispanics with T2D and vitamin D insufficiency/deficiency. Measures on reducing serum levels of AGEs and improving sRAGE and vitamin D are warranted in these populations for risk reduction of CVD. Funding Sources Partial funding for this research was provided through an NIH/NIDDK sponsored grant.

Sign in / Sign up

Export Citation Format

Share Document